March 24, 2009 the Honorable Harry Reid the Honorable Mitch
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Fully Human Domain Antibody Therapeutics: the Best of Both Worlds
Drug Discovery Fully Human Domain Antibody Therapeutics: The Best of Both Worlds By combining the therapeutic benefits of small molecule drugs with those of fully human antibodies, Domain Antibodies are expected to have strong therapeutic and commercial potential. By Robert Connelly at Domantis Robert Connelly is Chief Executive Officer of Domantis. He has over 22 years’ commercial experience of the life science sector, including that gained in the fields of diagnostics, drug discovery technologies and antibody therapeutics. Prior to joining Domantis, he was CEO of Veritas Pharmaceuticals (Los Angeles, USA), an in vivo imaging start-up company. He spent over five years with IGEN International, latterly as Senior Vice President and General Manager, Life Sciences, where he took part in the company’s IPO and financing rounds, raising $130 million. The first 11 years of his career were spent at Abbott Laboratories in sales, marketing and management positions. Domain Antibodies (dAbs) are the smallest functional variable regions of either the heavy (VH) or light (VL) binding units of antibodies. At Domantis, we are chains of human antibodies. Domantis scientists applying our proprietary know-how in dAbs to deliver have used the variable domains sequences of human human therapies that address large, unmet medical antibodies to create a series of large and highly needs in areas such as inflammation, cancer and functional libraries of fully human dAbs, with each autoimmune diseases. Three and a half years after library comprising at least 1010 different dAbs. The opening our laboratories, we have a dozen proprietary dAbs selected from these libraries are both specific therapeutic programmes underway, and an additional for their biological target and are well folded and eight therapeutic programmes with partners. -
IN the COURT of CHANCERY of the STATE of DELAWARE in Re
IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE In re PEPSIAMERICAS, INC. : Consolidated C.A. No. 4530-VCS SHAREHOLDERS LITIGATION : VERIFIED CONSOLIDATED CLASS ACTION COMPLAINT Plaintiffs Philadelphia Public Employees Retirement System (“Philadelphia PERS”), The General Retirement System of the City of Detroit (“Detroit General”), The Police and Fire Retirement System of the City of Detroit (“Detroit P&F”), the City of Ann Arbor Employees’ Retirement System (“Ann Arbor”) and Beverly Rosman (“Rosman,” and collectively with Philadelphia PERS, Detroit General, Detroit P&F and Ann Arbor, “Plaintiffs”), by and through their undersigned counsel, upon knowledge as to themselves and upon information and belief as to all other matters, allege as follows: NATURE OF THE ACTION 1. Plaintiffs are holders of common stock of PepsiAmericas, Inc. (“PAS” or the “Company”). Plaintiffs bring this action individually and as a class action on behalf of all holders of PAS common stock other than the defendants and their affiliates. Plaintiffs seek injunctive and other equitable relief in connection with the proposal of PepsiCo, Inc. (“PepsiCo”) to acquire all of the PAS’ outstanding shares that PepsiCo does not already own for a combination of cash and stock valuing PAS at $23.27 per share (the “Proposed Merger”). 2. PepsiCo simultaneously offered to acquire Pepsi Bottling Group, Inc. (“PBG” and with PAS, the “Companies”) at $29.50 per share, and has made consummation of a merger with either bottler contingent on consummating a merger with the other. PepsiCo’s offers are timed and structured to favor PepsiCo and promise a paltry 17.1 percent premium over the closing prices of the Companies’ stock on April 17, 2009, the last trading day prior to PepsiCo’s announcement of the Proposed Merger. -
2019 SEC Form 10-K (PDF File)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-14905 BERKSHIRE HATHAWAY INC. (Exact name of Registrant as specified in its charter) Delaware 47-0813844 State or other jurisdiction of (I.R.S. Employer incorporation or organization Identification No.) 3555 Farnam Street, Omaha, Nebraska 68131 (Address of principal executive office) (Zip Code) Registrant’s telephone number, including area code (402) 346-1400 Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbols Name of each exchange on which registered Class A Common Stock BRK.A New York Stock Exchange Class B Common Stock BRK.B New York Stock Exchange 0.750% Senior Notes due 2023 BRK23 New York Stock Exchange 1.125% Senior Notes due 2027 BRK27 New York Stock Exchange 1.625% Senior Notes due 2035 BRK35 New York Stock Exchange 0.500% Senior Notes due 2020 BRK20 New York Stock Exchange 1.300% Senior Notes due 2024 BRK24 New York Stock Exchange 2.150% Senior Notes due 2028 BRK28 New York Stock Exchange 0.250% Senior Notes due 2021 BRK21 New York Stock Exchange 0.625% Senior Notes due 2023 BRK23A New York Stock Exchange 2.375% Senior Notes due 2039 BRK39 New York Stock Exchange 2.625% Senior Notes due 2059 BRK59 New York Stock Exchange Securities registered pursuant to Section 12(g) of the Act: NONE Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. -
Team Captain Guide AIDS Run & Walk Chicago Saturday, October 2, 2010
Team Captain Guide AIDS Run & Walk Chicago Saturday, October 2, 2010 AIDS Run & Walk Chicago 2010 Saturday, October 2, 2010 Grant Park Team Captain Guide Table of Contents What is AIDS Run & Walk Chicago……………………………………. 3 Event Details ..………………………………………………………………….. 4 Preparing for Event Day …………………………………………………… 5 Team Building Tips …………………………………………………………… 6 Fundraising Tools ….…………………………………………………………. 7 Team Information Form …..………………………………………………. 8 Team Supplies Form ………………………………………………………… 9 Fundraising Form ……………………….……………………………………. 10 Online Fundraising Road Map ….……………………….…………….. 11 Participant Registration Form ………………………………………….. 12 Volunteer Information……………………………………………………… 13 Matching Gift Companies ………………………………………………… 14 2 About AIDS Run & Walk Chicago What is AIDS Run & Walk Chicago? AIDS Run & Walk Chicago is the largest AIDS-based outdoor fundraising event in the Midwest. Since its inception in 2001, AIDS Run & Walk Chicago has raised more than $3 million net to fight HIV/AIDS throughout the Chicagoland area. In 2009, more than 200 Teams joined forces to walk, run, and raise money in the fight against AIDS. With your help, we can surpass our goal of registering more than 300 Teams and raising $500,000 net! The AIDS Run & Walk Chicago Course takes place along the city’s lakefront, featuring Chicago’s famous skyline. Whether your teammates decide to run or walk along this spectacular course, all participants will be provided with the official AIDS Run & Walk Chicago T-Shirt, Race Bib, entertainment along the course, pre and post event activities, as well as lunch and treats! What Organizations Benefit from AIDS Run & Walk Chicago? AIDS Run & Walk Chicago benefits the AIDS Foundation of Chicago (AFC). AFC is the Midwest’s largest private source of philanthropic support for HIV/AIDS, a model of service coordination and Illinois’ principle advocate for people affected by HIV/AIDS. -
Past Award Winners 2007
GPLA booklet 04 new 9/28/04 6:59 PM Page 37 U.S. Environmental Protection Agency • U.S. Department of Energy • Center for Resource Solutions 2007 Green Power Leadership Awards The 2007 Green Power Leadership Awards are hosted by the United States Environmental Protection Agency (EPA), the United States Department of Energy (DOE), and the Center for Resource Solutions (CRS). EPA and DOE recognize leading green power purchasers and green power suppliers respectively. CRS recognizes leading organizations and individuals building the market for green power. The Green Power Leadership Awards for purchasers is a recognition program of the EPA Green Power Partnership, a voluntary program working to reduce the environmental impact of electricity use by fostering development of the voluntary green power market. The Partnership provides technical assistance and public recognition to organizations that commit to using green power for a portion of their electricity needs. Partners in the program include Fortune 500 companies, states, federal agencies, universities, and leading organizations around the country that have made a commitment to green power. For the 2007 green power supplier and purchaser awards, two panels of judges reviewed nearly 100 nominations through a national competitive review process. Purchasers were evaluated based upon the size and characteristics of their green power commitment, ingenuity used to overcome barriers, internal and external communication efforts, and overall renewable energy strategy. Recognition of these companies falls into three categories: On-site Generation, Green Power Purchasing, and Green Power Partner of the Year. Suppliers were evaluated based on the following criteria: technologies utilized, total sales, evidence of annual audit to verify procurement and sales, amount of green power supplied, and number of customers served. -
Inleadership
IN LEADERSHIP How Minnesota’s Top 100 Public Companies Rank The 2009 Minnesota Census of Women in Corporate Leadership Report produced by St. Catherine University and the Minnesota Women’s Economic Roundtable A Statewide Wakeup Call The second annual Minnesota Census of Women in Corporate Leadership reveals that women remain an underutilized resource in the top ranks of public companies. Consider the evidence: Kudos and Contributions Twenty-seven of the top 100 public companies in This initiative has been made possible by many individuals • Minnesota have no women board members. and organizations. The report was underwritten by Spencer Stuart, St. Catherine University, and the Minnesota Women’s Forty-one of the top 100 public companies have only Economic Roundtable. • one woman on their boards. Support for both the report and the Forum was provided by Women hold only 15 percent of the Section 16b Twin Cities Business magazine and other sponsoring organiza- • (Securities and Exchange Commission) executive tions (see pages 26 to 28 of this report). Special thanks to the officer positions in Minnesota’s top 100 public volunteers who made up this year’s steering committee (see companies. the report’s final page). Without their tireless efforts, neither the report nor the Forum luncheon would have been possible. Nineteen of the top 100 public companies have no • women involved with leadership — either as directors Now, we turn to our readers — our state’s corporate and small- or executive officers. business leaders — to carry on this work, in the hope that future editions of The Minnesota Census will show progress We ask that women and men view this report as a wakeup on behalf of our state’s business climate and, subsequently, call, one whose findings deserve and demand to be shared all people in Minnesota. -
BMW of North America, LLC NJ ""K"" Line America, Inc. VA 1199
The plan sponsors listed below have at least one application for the Retiree Drug Subsidy (RDS) program in an "Approved" status for a plan year ending in 2010 as of February 4, 2011. The state listed for each sponsor is the state provided by the sponsor on the application for the subsidy. This state may, or may not, be where the majority of the plan sponsor's retirees reside or where the plan sponsor is headquartered. This list will be updated periodically. Plan Plan Sponsor Business Name Sponsor State : BMW of North America, LLC NJ ""K"" Line America, Inc. VA 1199 SEIU Greater New York Benefit Fund NY 1199 SEIU National Benefit Fund NY 3M Company MN 4th District IBEW Health Fund WV A-C RETIREES' VOLUNTARY BENFITS PLAN WI A. DUDA & SONS, INC. FL A. SCHULMAN, INC OH A. T. Massey Coal Company, Inc. VA A&E Television Networks NY AAA EAST PENN PA AARP DC ABB Inc. CT Abbott Laboratories IL Abbott Pharmaceuticals PR Ltd. PR Acadia Parish School Board LA Accenture LLP IL Accuride Corporation IN ACF Industries LLC MO ACGME IL Acton Health Insurance Trust MA Actuant Corporation WI Adirondack Central School NY Administrative Office of the Pennsylvania Courts PA Adventist Risk Management MD Advisory Services OH AEGON USA, Inc. IA AFL-CIO Health and Welfare Trust DC AFSCME DC AFSCME Council 31 IL afscme d.c. 47 health & welfare fund PA AFSCME District Council 33 Health and Welfare Plan PA AFTRA Health Fund NY AGC FLAT GLASS NORTH AMERICA INC TN Page 1 AGC-IUOE Local 701 Health & Welfare Trust Fund WA AGCO Corporation GA Agilent Technologies, Inc. -
3M Company (MMM)
COMPANY PROFILES 2008 The Research Group of Godsey & Gibb Associates compiled the following information in Godsey & Gibb Associates’ 2008 Company Profiles from Reuters’ Company Profiles. These reports are intended solely for the clients of Godsey & Gibb Associates and its affiliates. This material is for informational purposes only and is not intended to be a recommendation for the purchase or sale of any individual security. GODSEY & GIBB COMPANY PROFILES 2008 TABLE OF CONTENTS AFLAC Inc. (AFL)………………………………………………………………………………………. 1 AGL Resources Inc. (ATG)…………………………………………………………………………… 3 American Electric Power Co. Inc. (AEP)….………………………………………………………… 5 AT&T, Inc (T)…………………………………………………………………………………………… 7 Barrick Gold Corp. (ABX)……………………….……………………………………………………. 9 BB&T Corp. (BBT)………………………………………………………………..…………………… 10 BP, plc (BP)…………………………………………………………………………………….………. 12 Cisco Systems, Inc. (CSCO)……………………………………………………………….………… 13 Cognizant Technology Solutions (CTSH)……………………………………………………….….. 15 CVS Caremark Corp. (CVS)………………………………………………………………………….. 16 Dominion Resources, Inc. (D)………………………………………………….…………………….. 17 Emerson Electric Co. (EMR)………………………………………………………………………….. 19 Express Scripts, Inc. (ESRX)…………………………………………………………………..……… 23 ExxonMobil Corp. (XOM)………………………………………………………………….…………… 24 General Electric Company (GE)………………………………………………………………..……. 26 Gilead Sciences, Inc. (GILD)…………………………………………………………………………. 27 W.W. Grainger, Inc. (GWW)………………………………………………………………………….. 30 Hewlett-Packard Co. (HPQ)………………………………………………………………………….. 32 Integrys Energy Group, -
Lilly to Acquire Imclone Systems in $6.5 Billion Transaction
Lilly to Acquire ImClone Systems in $6.5 Billion Transaction Creates a Global Leader in Oncology Biopharmaceuticals Boosts Oncology Pipeline With Up to Three Promising Targeted Therapies in Phase III in 2009 INDIANAPOLIS and NEW YORK, Oct 06, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Eli Lilly and Company (NYSE: LLY) and ImClone Systems Inc. (Nasdaq: IMCL) today announced that the boards of directors of both companies have approved a definitive merger agreement under which Lilly will acquire ImClone through an all cash tender offer of $70.00 per share, or approximately $6.5 billion. The offer represents a premium of 51 percent to ImClone's closing stock price on July 30, 2008, the day before an acquisition offer for ImClone was made public. ImClone's board recommends that ImClone's shareholders tender their shares in the tender offer. Additionally, certain entities associated with ImClone's chairman, Carl C. Icahn, holding approximately 14 percent of ImClone's outstanding common stock, have agreed to tender their shares in the tender offer. This strategic combination will create one of the leading oncology franchises in the biopharmaceutical industry, offering both targeted therapies and oncolytic agents along with a pipeline spanning all phases of clinical development. The combined oncology portfolio will target a broader array of solid tumor types including lung, breast, ovarian, colorectal, head and neck, and pancreatic, positioning Lilly to pursue treatments of multiple cancers. Combining with ImClone will further strengthen Lilly's growing portfolio of first-in-class and best-in-class pharmaceutical products, enabling Lilly to better support oncologists, with the ultimate goal of delivering better outcomes for cancer patients. -
11/09/2016 Provider Subsystem Healthcare and Family Services Run Time: 20:25:21 Report Id 2794D051 Page: 01
MEDICAID SYSTEM (MMIS) ILLINOIS DEPARTMENT OF RUN DATE: 11/09/2016 PROVIDER SUBSYSTEM HEALTHCARE AND FAMILY SERVICES RUN TIME: 20:25:21 REPORT ID 2794D051 PAGE: 01 NUMERIC COMPLETE LIST OF PHARMACEUTICAL LABELERS WITH SIGNED REBATE AGREEMENTS IN EFFECT AS OF 01/01/2017 NDC NDC PREFIX LABELER NAME PREFIX LABELER NAME 00002 ELI LILLY AND COMPANY 00145 STIEFEL LABORATORIES, INC, 00003 E.R. SQUIBB & SONS, LLC. 00149 WARNER CHILCOTT PHARMACEUTICALS INC. 00004 HOFFMANN-LA ROCHE 00168 E FOUGERA AND CO. 00006 MERCK & CO., INC. 00169 NOVO NORDISK, INC. 00007 GLAXOSMITHKLINE 00172 IVAX PHARMACEUTICALS, INC. 00008 WYETH LABORATORIES 00173 GLAXOSMITHKLINE 00009 PFIZER, INC 00178 MISSION PHARMACAL COMPANY 00013 PFIZER, INC. 00182 GOLDLINE LABORATORIES, INC. 00015 MEAD JOHNSON AND COMPANY 00185 EON LABS, INC. 00023 ALLERGAN INC 00186 ASTRAZENECA LP 00024 SANOFI-AVENTIS, US LLC 00187 VALEANT PHARMACEUTICALS NORTH AMERICA 00025 PFIZER, INC. 00206 LEDERLE PIPERACILLIN 00026 BAYER HEALTHCARE LLC 00224 KONSYL PHARMACEUTICALS, INC. 00029 GLAXOSMITHKLINE 00225 B. F. ASCHER AND COMPANY, INC. 00032 SOLVAY PHARMACEUTICALS, INC. 00228 ACTAVIS ELIZABETH LLC 00037 MEDA PHARMACEUTICALS, INC. 00245 UPSHER-SMITH LABORATORIES, INC. 00039 SANOFI-AVENTIS, US LLC 00258 FOREST LABORATORIES INC 00046 AYERST LABORATORIES 00259 MERZ PHARMACEUTICALS 00049 PFIZER, INC 00264 B. BRAUN MEDICAL INC. 00051 UNIMED PHARMACEUTICALS, INC 00281 SAVAGE LABORATORIES 00052 ORGANON USA INC. 00299 GALDERMA LABORATORIES, L.P. 00053 CSL BEHRING 00300 TAP PHARMACEUTICALS INC 00054 ROXANE LABORATORIES, INC. 00310 ASTRAZENECA LP 00056 BRISTOL-MYERS SQUIBB PHARMA CO. 00327 GUARDIAN LABS DIV UNITED-GUARDIAN INC 00062 ORTHO MCNEIL PHARMACEUTICALS 00338 BAXTER HEALTHCARE CORPORATION 00064 HEALTHPOINT, LTD. 00378 MYLAN PHARMACEUTICALS, INC. -
UNIFIED LIST of UNITED STATES COMPANIES with Investments Or Loans in SOUTH AFRICA and NAMIBIA
UNIFIED LIST of UNITED STATES COMPANIES with Investments or Loans in SOUTH AFRICA and NAMIBIA Compiled from Existing Source Lists by PACIFIC NORTHWEST RESEARCH CENTER June 1985 Project Managers: ROGER WALKE Pacific Northwest Research Center RICHARD KNIGHT The Africa Fund (associated with the American Committee on Africa) 198 Broadway e New York, NY 10038 Published in cooperation with the United Nations Centre Against Apartheid UNIFIED LIST TABLE OF CONTENTS INTRODUCTION .................................................... 1 RANKING OF U.S. COMPANIES IN SOUTH AFRICA AND NAMIBIA .......... 3 Ranked by Number of Employees Ranked by Direct Investment (Assets) Ranked by Outstanding Loans/Underwritings Participated In Ranked by Total of Loans/Underwritings Participated In KEY TO THE UNIFIED LIST ........................................ 8 NOTES AND ABBREVIATIONS ....................................... 10 UNIFIED LIST ................................................... 11 APPENDIX ....................................................... 93 Parent Companies No Longer in South Africa or Namibia Parent Companies that MAY No Longer Be in South Africa or Namibia Accounting Firms Claiming No Ownership in South African Firm NUMBERED SOURCES ............................................... 94 GENERAL SOURCES ................................................ 95 Please read the sections KEY TO THE UNIFIED LIST and NOTES AND ABBREVIATIONS before using the Unified List. Special thanks for assistance on this project to Katherine Black, James Campbell, Mark Cheatham, Christina Cowger, Debra George(PNWRC), Steve Johnson (PNWRC), Maureen King, Carol Pritchett, and Stephanie Weber (PNWRC). o 1985 The Africa Fund and Pacific Northwest Research Center, Inc. INTRODUCTION This unified list on U.S. corporate involvement in South Africa and Namibia has been compiled to meet the needs of the divestment movement. Accurate information about U.S. corporate economic involvement is essential to divestment action. Over the past few years, a number of lists of U.S. -
2013 Annual Report
2013 Annual Report Letter to Shareholders 1 Financial Highlights 10 PepsiCo Board of Directors 11 PepsiCo Leadership 12 PepsiCo Form 10-K 13 Reconciliation of GAAP and Non-GAAP Information 141 Common Stock and Shareholder Information 144 “We delivered on, or exceeded, each and every one of the fi nancial goals we announced to shareholders at the beginning of the year.” INDRA K. NOOYI Dear Fellow Shareholders, PepsiCo Chairman and Chief Executive Offi cer Last year I described the dual goals we have unwaveringly pursued since we began our transformation back in 2007: continue to deliver the strong, consistent financial results our shareholders expect year after year, while at the same time investing in and transforming the company to ensure it is built for long-term, sustainable growth. In short, perform while we transform. Looking back, 2012 was an important year in PepsiCo’s transformation journey. We took the necessary actions to strengthen our company. We made significant invest- ments behind our largest global brands. And we changed our operating model — moving from a loose federation of countries and regions to a more efficient and effective model that leverages PepsiCo’s talent, capabilities and resources globally. In 2013, we continued to reinforce these actions and began to realize the benefits. Despite a very challenging operating environment that included economic instability and uncertainty in many of our key markets around the world, we delivered on, or exceeded, each and every one of the financial goals we announced to shareholders at the 1 beginning of the year. Our performance in 2013 was strong: • Our organic revenue grew 4%.